Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Accured Expenses (2017 - 2025)

CorMedix's Change in Accured Expenses history spans 11 years, with the latest figure at $52.3 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 248.94% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $100.8 million, up 338.42%, while the annual FY2025 figure was $100.8 million, 338.42% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $52.3 million at CorMedix, down from $54.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $54.7 million in Q3 2025 and bottomed at -$6.6 million in Q2 2025.
  • The 5-year median for Change in Accured Expenses is $331443.0 (2025), against an average of $7.3 million.
  • The largest annual shift saw Change in Accured Expenses crashed 1164.16% in 2021 before it surged 5908.45% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$13900.0 in 2021, then soared by 5908.45% to $807375.0 in 2022, then plummeted by 209.6% to -$884872.0 in 2023, then soared by 1793.16% to $15.0 million in 2024, then soared by 248.94% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Change in Accured Expenses are $52.3 million (Q4 2025), $54.7 million (Q3 2025), and -$6.6 million (Q2 2025).